Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Milademetan (DS 3032b), an Oral MDM2 Inhibitor, In Dose Escalation as a Single Agent and In Dose Escalation/Expansion In Combination With 5 Azacitidine In Subjects With Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

NCT02319369 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT02319369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02319369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Milademetan (DS 3032b), an Oral MDM2 Inhibitor, In Dose Escalation as a Single Agent and In Dose Escalation/Expansion In Combination With 5 Azacitidine In Subjects With Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Terminated
Start date
November 25, 2014
Completion date
August 21, 2020
Enrollment
74 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, myelodysplastic syndrome